Immune checkpoint inhibitors are important medications that boost the immune system’s response against certain cancers; however, they tend to be ineffective against glioblastoma, the most deadly primary brain tumour in adults. New research in mice led by investigators at Massachusetts General Hospital (MGH) and the University of Florida reveals a promising strategy that makes glioblastoma susceptible to these medications.

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

Artificial intelligence (AI) technology developed by the RIKEN Center for Advanced Intelligence Project (AIP) in Japan has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors.

A fundamental change in our understanding of the childhood kidney cancer Wilms’ tumour is on the horizon, after the discovery of its earliest genetic root by scientists at the Wellcome Sanger Institute and their collaborators.

Physicians who treat patients with triple negative breast cancer have two new ways to predict which patients may benefit most from the well-established post-surgery treatment known as AC chemotherapy, short for adjuvant doxorubicin and cyclophosphamide.

Mining the rich uncharted territory of the genome or genetic material of a cancer cell has yielded gold for Princess Margaret scientists: new protein targets for drug development against prostate cancer.

A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell – nucleotide metabolism – to help identify new drugs that specifically and potently block processes that are essential for cancer cell growth.

Promising results for the UM171 molecule in blood stem cell transplants for patients with acute blood cancers.

Fox Chase Cancer Center researchers have determined that RNA-based next generation sequencing picks up gene fusions in sarcoma tumours that traditional gene testing may not.

A discussion of a new genomic method, named CUTseq, which can assess the amount and type of CNAs in many different parts of the same tumour, at a much lower cost than existing technologies.